In a further sign of growing interest among large drugmakers in an emerging target for cancer immunotherapy drugs, a company in the space is getting an equity investment from one of the world’s ...

CD47-directed therapies offer a novel immuno-oncology strategy for engaging the innate immune system in a variety of tumor types. Early results provide a rationale for expanding trials with promising ...

Phagocytosis relies on a balance between prophagocytic (“eat me”) and antiphagocytic (“don't eat me”) signals on target cells 1,2,3. CD47, initially observed on stem cells, is a transmembrane protein ...

ALX Oncology’s CD47-blocker evorpacept, in combination with MSD’s blockbuster Keytruda (pembrolizumab), has failed to show benefit in two Phase II trials. The combination was being investigated in the ...

CD47-null femoral fractures show reduced bone formation, but increased tissue mineral density. µCT analysis of transverse femoral fracture in WT (n = 9) and CD47-null (n = 11-14) mice at 10- and ...